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Background: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against
multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive
treatment of osteomyelitis.
Methods: In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and
Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means
of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was
performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed
osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/
persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic
side effects connected with the BAG use.
Results: In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after
24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed
for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the
follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed
further surgical procedures. BAG-S53P4 was generally well tolerated.
Conclusions: The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for
the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in
immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics.
Trial registration: Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332.
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Besides haematogenous osteomyelitis, any kind of bone or
soft tissue trauma or surgery where pathogens can reach
the bone may cause infection. Osteomyelitis hallmarks
consist of progressive bone destruction and the formation
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stated.and gram-negative bacilli are the pathogens most com-
monly involved [1]. Treatment usually includes surgical
debridement of the necrotic and infected tissue that har-
bours bacteria and systemic antibiotics [2]. Complete
infection eradication is still considered a challenging re-
sult, depending, among other variables, on the anatomo-
pathological aspect of the disease and host type [3,4].
Moreover, various degrees of bone loss are frequently
encountered in chronic osteomyelitis, due to the septic
process per se, to the related inflammatory reactions and
to the necessary surgical debridement, further compli-
cating treatment and reconstruction of the affectedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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free flaps, bone transport, or, more often, with local ap-
plication of antibiotic-loaded polymethyl methacrylate
(PMMA) beads, bone grafts or bone substitutes, aimed at
filling the dead space while delivering antibacterial com-
pounds locally [5-9]. Bioactive glasses (BAGs) have been
recently shown to have antibacterial, osteoconductive and
angiogenic properties [10-15]. The BAG-S53P4 compo-
sition (SiO2, Na2O, CaO, P2O5) facilitates tissue growth by
binding chemically the bone matrix and thereby promote
the formation of new bone in the implanted area. In par-
ticular, antibacterial properties have been put in cor-
relation with a local pH and osmotic pressure increase,
since sodium and calcium ions and phosphorus salts make
the environment hostile for bacterial adhesion and the
subsequent proliferation of microorganisms that cause in-
fection [15,16]. Despite the increasing amount of in vitro
evidence concerning BAGs antibacterial properties, and
the long term clinical use in treating chronically in-
fected bone in cranio-maxillofacial indications [17,18],
only two clinical studies, on a limited series of patients,
have explored the potential use of BAGs for the treat-
ment of chronic osteomyelitis so far in an orthopaedic
setting [14,19].
Nonetheless BAGs seem to be particularly interesting
in this application, since one version (S53P4, BonAlive®,
Finland) is an approved medical device in Europe for
the treatment of osteomyelitis, being the only biomate-
rial, to our knowledge, approved for local application
for the treatment of bone infections without being pre-
loaded with antibiotics or acting as an antibiotic carrier.
Aims of the present study were: i) to explore the
in vitro antibacterial activity of BAG S53P4 against
multi-resistant microorganisms commonly involved in
osteomyelitis and ii) to report on the largest series pub-
lished to date in the treatment of osteomyelitis with sur-
gical debridement and local application of BAG S53P4.Methods
In vitro study
Preparation and conditioning of bioglass
Tubes containing BAG-S53P4 granules (diameter of
500–800 μm) (BonAlive Biomaterials Ltd, Turku,
Finland) or inert glass of similar size used as control
(R1350 Iittala clear, Iittala, Finland) were prepared at a
final concentration of 800 mg/mL and 400 mg/mL in
Tryptic Soy Broth (TSB; Biomerieux Marcy l’Etoile,
France). Conditioning of bioglass was obtained by in-
cubation of test tubes for 48 hours at 37°C in order
to promote the granules packaging. Value of pH was
measured by pH meter at regular intervals to deter-
mine ions release and pH changing suggestive for
conditioning.Evaluation of antibacterial activity
In order to evaluate the antibacterial activity of BAG-
S53P4, methicillin resistant S. aureus (MRSA) (n = 5),
methicillin resistant Staphylococcus epidermidis (MRSE)
(n = 5), Pseudomonas aeruginosa (n = 5) and Acinetobac-
ter baumannii (n = 5) isolated from patients affected by
chronic (> 6 months duration) osteomyelitis were con-
sidered. Two hundred microliters of a bacterial suspen-
sion (106 CFU/mL) of each strain were inoculated into
tubes containing BAG-S53P4 or inert glass. Tubes were
incubated at 37°C in aerobic atmosphere and after 24,
48 and 72 hours of incubation 10 μL of proper diluted
medium were plated on Trypticase Soy Agar plates for
colonies counts. Values were expressed as log10CFU/mL.
Tests were performed in duplicate.
In vivo study
A prospective, cohort, observational study was performed
from October 2010 to May 2013 on 27 patients (18 males,
9 females; mean age 44 ± 14 yrs, range 20–80 yrs) with a
clinically and radiologically diagnosed osteomyelitis of
the long bones and candidate to surgical debridement and
defect filling with antibacterial bone substitute. All the
patients gave their informed consent to participate in the
study which was approved by the Ethics committee of our
Institution and conducted in accordance with institutional
standards.
Inclusion criteria were: age > 18 years, the presence of
osteomyelitis of a long bone for at least 6 months requi-
ring surgical debridement and bone defect filling; ex-
clusion criteria were: need for local plastic procedures,
segmental bone defects, associated septic arthritis.
Primary endpoint of the study was the absence of in-
fection recurrence/persistence at follow-up, defined as:
absence of draining sinus or local clinical signs of acute
inflammation (redness, swelling, warmth, pain), elevated
values of C reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR) and no need for further surgery
whenever during follow-up.
Secondary endpoint was the absence of local or sys-
temic side effects connected with the use of the BAG.
Patients characteristics
Patients characteristics are reported in Table 1. Average
symptoms duration at the time of surgery was 17.8 ±
14 months (range: 5–60 months). Mean previous surgeries
before index operation were 1.8 ± 1.3 (range: 0–5). Patho-
genesis of the infection was haematogenous in 8 patients,
post-traumatic in 9 and post-surgical in 10. Infection was
localized at the tibia in 18 cases, at the femur in 8, at the
humerus or in the metatarsus in one patient each. One pa-
tient presented a bifocal localization (tibia and femur).
According to Cierny & Mader anatomo-pathological
classification [3], 8 patients were classified as Stage 1
Table 1 Patients’ characteristics
Patient Age (years) Sex Site Previous
surgeries
Infection duration
(months)
Pathogenesis Stage Host type
1 35 F Tibia 3 12 Post-traumatic 4 A
2 50 M Femur 5 60 Post-traumatic 3 B (smoker)
3 60 M Femur 2 18 Haematogenous 1 B (lymphoma, chemotherapy)
4 47 M Tibia 4 54 Haematogenous 1 C (smoker, vasculopathy, diabetes)
5 35 M Femur 1 18 Post-traumatic 3 A
6 23 M Tibia 1 9 Post-surgical 3 A
7 80 M Tibia 3 38 Post-surgical 3 B (psoriasis, corticosteroids)
8 41 M Tibia 2 12 Post-surgical 3 A
9 38 M Femur 1 36 Post-surgical 3 A
10 28 M Femur 1 12 Post-surgical 3 A
11 40 F Femur 1 12 Post-traumatic 3 B (tumor, radiotherapy)
12 50 F Humerus 0 10 Haematogenous 1 B (rheumatoid arthritis)
13 40 F Tibia 3 24 Post-traumatic 2 B ( peripheral vasculopathy)
14 60 M Tibia 2 12 Post-traumatic 4 B (smoker)
15 44 M Tibia 3 24 Post-traumatic 3 B (smoker, alcol abuse)
16 36 F Tibia 0 6 Haematogenous 1 A
17 55 M Tibia 2 12 Post-surgical 3 B (smoker, peripheral vasculopathy)
18 20 M Tibia 0 6 Haematogenous 1 A
19 36 M Tibia 2 6 Post-surgical 3 A
20 40 M Femur 2 12 Post-surgical 3 B (smoker, peripheral vasculopathy)
21 30 M Tibia 0 10 Haematogenous 1 B (tetraplegia, recurrent pneumonia and
urinary tract infection)
22 50 F Tibia 2 24 Post-traumatic 3 B (smoker)
23 52 F Tibia 2 12 Haematogenous 1 B (diabetes, peripheral neuropathy)
24 50 M Tibia 2 12 Post-surgical 3 B (Churg-Strauss disease,
immunosuppression)
25 61 F Foot 2 12 Post-surgical 3 B (diabetes)
26 60 M Tibia 2 6 Post-traumatic 3 B (smoker)
27 20 F Tibia + Femur 0 12 Haematogenous 1 B (immunosuppressive therapy)
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Host type was classified according to McPherson [4], 9
patients were considered Type A , 17 as Type B and 1 as
Type C (Table 1).
All patients underwent pre-operative clinical and la-
boratory tests evaluation, x-ray, CT and MRI scan. Con-
cerning clinical presentation and local inflammatory
signs (redness, swelling, pain, local warmth), 8 patients
were considered to have an acute infection presentation
(all inflammatory signs present), 7 subacute (presence of at
least two inflammatory signs) and 12 a chronic infection
(presence of only one or no signs of local inflammation).
Ten patients had a draining sinus at the time of surgery.
Average pre-operative ESR and CRP values were 58 ±
41 mm/hr (range: 18 – 115 mm/hr) and 9.8 ± 7.3 mg/dL
(range: 0.8 – 18 mg/dL), respectively.Surgical procedure
Surgery was performed according to a same protocol in
all the patients and by the same surgical team. In brief,
with the patient laying supine, a surgical incision was
made at the site of the osteomyelitic lesion, staying on
previous scar, when present. After accurate dissection of
soft tissues, bone was exposed. In some cases intra-
operative fluoroscopy was used to localize the lesion.
Removal of all foreign materials, when present (plates,
screws, cerclages, bone substitutes, etc.), was then per-
formed. Opening of the osteomyelitc focus was usually
obtained with a surgical oscillating saw and osteotomes,
in order to make a bone window of approximately 1 to
2 cm width and 2 to 8 cm length, depending on the in-
fected site. Accurate debridement of the medullary canal
was then performed with curettes, osteotomes and
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all necrotic tissues, sequestra and infected bone and soft
tissues. Medullary canal proximal and distal to the lesion
was opened. Repeated lavage with saline and accurate
haemostasis was then performed. The use of tourniquet
was avoided or restricted to a minimum.
After debridement and re-gowning and re-gloving, the
bone defect was filled with BAG-S53P4 granules. No
local antibiotics were added. Mean BAG volume used
was 21.0 ± 10.9 mL (range: 2 – 60 mL). In two patients
(1 and 14), classified as having a septic non-union, an
external fixator was also implanted at the end of the sur-
gical procedure.
All patients received thrombohaembolic prophylaxis
with low weight heparin for four to six weeks and systemic
antibiotic therapy with two antibiotics, targeted to the
isolated microorganism(s) for four to six weeks post-
operatively. In case of negative cultures a combination of
two antibiotics was also empirically administered (usually
intravenous vancomycin or teicoplanin and meropenem
during hospital stay and then levofloxacin and rifampicin
orally after discharge home).
Microbiological analysis
Microbiological analysis was conducted on the removed
foreign material, when present, swabs and tissue samples
(n = 5–8). Samples were aseptically collected at the site
of surgery and delivered to the laboratory within
30 minutes.
Tissue samples and foreign materials were processed by
sonication as routinely performed in our laboratory [20].
Briefly, the container was filled with sterile saline until
complete submersion of the sample, carefully sealed and
sonicated in an ultrasound bath (VWR, Milan, Italy) for
5 minutes with a frequency of 30 kHz and a power output
of 300 W at room temperature. At the end of sonication,
the obtained fluids were accurately mixed, centrifuged at
3000 rpm for 10 minutes and resuspended in a volume of
about 1.5 mL.
Swabs and 100 μl of sonicated samples were seeded
onto Chocolate Agar (CA), Mannitol Salt agar (MSA),
MacConkey agar (MC) Schaedler Blood Agar (SBA),
Sabouraud Agar (SA,) Brain Heart Infusion broth (BHI)
and Thioglycollate Broth (TH). CA and MC plates were
incubated at 37°C for 24 hours in 10% CO2 enriched
atmosphere and aerobiosis, respectively. Incubation of
MSA and SA lasted 48 hrs in aerobiosis while SBA was
incubated in anaerobiosis at 37°C for 48 hours. After incu-
bation, growth and colonies counts were recorded for
both aerobes and anaerobes. BHI and TH were incubated
for 15 days at 37°C and checked daily for microbial
growth.
Identification was performed at biochemical (Vitek2
Compact, Biomerieux, Marcy l’Etoile, France) andgenotypic level. Genotypical identification was performed
by DNA sequencing of about 80 pb of variable regions
V1 and V3 of the 16S rRNA gene by Pyrosequencing
(PSQ96RA, Diatech, Jesi, Italy) [21]. Obtained sequences
were inserted in BLAST (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) to perform accurate identification.
Post-surgical follow-up
All the patients underwent clinical and laboratory tests
evaluation, including haemocromocitometric analysis
with leukocyte formula and determination of ALT, AST,
creatinine, CRP and ESR, at 15 and 30 days and at 3, 6,
9, 12, 18, 24 months after surgery.
X-ray examination was performed at 6, 12 and 24 months
post-operatively.
Any early and late side effect presumably due to the
local application of BAG were recorded at each visit.
Statistical analysis
Differences in colonies counts between BAG-S53P4 and
inert glass were evaluated by means of two-way analysis
of variance (ANOVA) and Bonferroni’s t test.
Results
In vitro study
During conditioning, a steady increase of pH toward
basic values occurred in test tubes containing bioglass
while no changes were observed for inert glass, which
maintained a neutral pH. After 48 hours, pH values were
11.4 and 7.2 for BAG-S53P4 and inert glass, respectively,
thus indicating occurrence of bioglass conditioning.
As shown in Figure 1, antimicrobial activity of the two
different concentrations of conditioned BAG-S53P4 glass
appears to be rather similar for all the tested strains.
After 24 hours of incubation with bioglass a significant
decrease of about 5 logs of CFU/mL for all the tested
species was observed. After 48 hours there was a further
decrease in MRSA and P. aeruginosa colony counts
while no bacterial growth was detected for MRSE and
A. baumannii. After 72 hours of incubation a total ab-
sence of growth was observed for all clinical isolates. By
contrast, all the tested strains showed an exponential in-
crease in colony number in the tubes with inert glass.
Statistical analysis evidenced significant differences vs
time 0 and among treatment groups at all time tested
with p values <0.002.
In vivo study
Average hospital stay was 8.0 ± 6.9 days (range: 4–18 days).
The isolated microorganisms are reported in Table 2. The
most common isolated pathogen was S. aureus (18 pa-
tients, 10 with MRSA). In 5 patients a mixed flora was
found, while in 4 patients cultures yielded negative results.
Figure 1 In vitro antibacterial activity of Bioglass S53P4 against methicillin-resistant S. aureus (a), P. aeruginosa (b), methicillin resistant
S. epidermidis (c) and A. baumanni (d). Data are mean ± S.D. of counts from 5 strains for each species. Circle: Bioglass S53P4 800 mg/mL;
Square: Bioglass S53P4 400 mg/mL; Triangles: inert glass 800 mg/mL and Crosses: inert glass 400 mg/mL.
Drago et al. BMC Infectious Diseases 2013, 13:584 Page 5 of 8
http://www.biomedcentral.com/1471-2334/13/584At a mean follow-up of 17.8 ± 6.1 months (range: 9 to
30 months), 24 patients (88.9%) did not demonstrate any
sign of infection, while 2 showed an infection recurrence
at 6 months from index operation and one more needed
further surgical procedures (local muscular flap for de-
layed skin necrosis and bone exposure). Patient 21 died
13 months after surgery for the sequelae of recurrent
pneumonia. No recurrence at the osteomyelitis site was
evident at clinical or x-ray examination.
Patient 12 showed a prolonged (four weeks) serum
wound leakage, requiring the application of three stitches
and healed without further complications. The patient did
not show any infection recurrence at the latest follow-up.
No other side effects were recorded.
X-ray examination showed incorporation of the bio-
glass within the host bone and no signs of osteolysis or
periosteal reactions. However, the biomaterial was still
visible at x-ray examination at two years from surgery.
Discussion
This is the first study reporting on the in vitro antibac-
terial effect of BAG-S53P4, compared to inert glass,
against multi-resistant pathogen isolated in chronic
osteomyelitis foci.We also report the largest continuous series of patients
affected by chronic osteomyelitis of the long bones,
treated according to the same protocol, including surgical
debridement and bone defect filling with BAG-S53P4,
without any local antibiotic administration.
Until now autograft bone with its osteoinductive po-
tential has been the material of choice when bone graft
is needed [22]; but in the presence of infection it is con-
sidered contraindicated [23]. Many different methods
have been used to treat the bone defect and the infec-
tion, including bone transport through an external fixa-
tor, surgical debridement and bone defect filling with
antibiotic-impregnated polymethylmethacrylate (PMMA)
or antibiotic-loaded bone grafts or bone substitutes, but
clinical resolution still remains a challenge, while per-
sistent serum wound leakage using calcium-based bone
substitutes is a rather frequent occurrence [23].
Bioactive materials are defined as materials stimulating
a specific biological response at the interface between the
material and tissue, resulting in the formation of a bond
between them [24]. In particular, bioactive glasses are
bone substitutes with bone binding and antibacterial pro-
perties, first introduced in 1969 [24,25]. Since the degree
of bone bonding capacity and resorption rates are highly
Table 2 Post-surgical data
Patient Microorganism Follow-up
(months)
Infection
recurrence/
persistance
1 Multi-resistant Enterococcus
faecium
30 None
2 MRSA 30 None
3 MRSA 26 None
4 MSSA 25 None
5 Pseudomonas aeruginosa +
Enterococcus faecium
24 None
6 MRSA 24 None
7 P. aeruginosa +MSSA +
Enterococcus spp.
24 Recurrence after
6 months
8 Negative 22 None
9 MSSA 20 None
10 MRSA 20 None
11 Negative 19 None
12 MSSA 18 None
13 P. aeruginosa +MSSA 17 Plastic flap after
8 months
14 MRSA + Staphylococcus
lugdunensis
16 None
15 Staphylococcus hominis 16 None
16 MSSA 15 None
17 MSSE 15 None
18 MRSA + GABHS 14 None
19 Negative 14 None
20 MRSE 14 None
21 MRSA 13 None
22 MRSA 12 Recurrence after
6 months
23 MSSA 12 None
24 MRSA 12 None
25 Negative 10 None
26 MRSA 9 None
27 MSSA 9 None
MRSA: methicillin resistant S. aureus; MSSA: methicillin susceptible S. aureus;
GABHS: Group A β-haemolytic streptococcus.
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each bioglass is needed in order to improve their clinical
use.
The present study had double aim: first to confirm,
through in vitro tests, the antibacterial properties of BAG-
S53P4 against multiresistant bacterial strains, isolated
from patients with chronic osteomyelitis. Secondarily, to
evaluate the in vivo efficacy and safety of BAG-S53P4 as a
bone graft substitute in clinical setting by studying a con-
tinuous series of patients affected by chronic osteomyelitis
of the long bones.Results obtained in the first step of the study indicate
a notable antibacterial activity of bioglass BAG-S53P4
granules at two different concentrations (800 mg/mL
and 400 mg/mL) against methicillin resistant S. aureus
and S. epidermidis, and multiresistant P. aeruginosa and
A. baumannii. These results are in line and extend the
antibacterial spectrum of activity of BAG-S53P4, pre-
viously reported [13,15,27]; to date, to our knowledge,
no bacterial resistance to the action of this compound
has been described.
Bioglass antibacterial property is probably due to the
ability of granules to release ions, such as sodium, calcium,
phosphate and silicate in aqueous conditions, which
increase the pH value and the osmotic pressure of the
environment [28]. For this reason, BAG-S53P4 granules
need to be conditioned in order to create the right hostile
environment for bacterial growth. In this study, in vitro
conditioning was performed by leaving the glass in contact
with an aqueous solution in order to activate the release
of the ions responsible of raising the pH. The chosen con-
ditioning time was 48 hours since no significant variations
of pH were recorded if conditioning was further pro-
longed. Such a long time could be explained by the fact
that in the experimental conditions used in this study, the
contact surface between the aqueous environment and the
bioglass was rather limited.
Furthermore bioactive glass has been proved to have an-
giogenic properties in vitro [10]. Vascularization and new
bone formation have been observed to be faster in defects
filled with BAG-S53P4 than in hydroxyapatite-filled de-
fects. Initial fibrous tissue formation related to a consi-
derable amount of blood vessels was also more rapid in
the BAG filled defects [22,29]. Similar findings have been
observed by Virolainen et al. who observed that the BAG
surface is not only conductive but also osteoproductive in
promoting migration, replication, and differentiation of
osteogenic cells and their matrix production [30]. This
phenomenon may be beneficial in treatment of osteomye-
litis, as the antibacterial, osteoproductive and angiogenesis
promoting properties observed for BAGs may remain over
a long period.
The safety and efficacy of BAG-S53P4 have been clini-
cally evaluated in randomized prospective clinical trials in
the field of spine, benign bone tumour and trauma surgery
and for the treatment of bone defects in oral and maxillo-
facial surgery [31-34]. Despite the in vitro evidence of
antibacterial efficacy of BAG-S53P4, a relatively limited
number of clinical studies have explored the potential use
of these materials for the treatment of chronic osteomye-
litis. To our best knowledge, only two studies, on limi-
ted patients’ populations have been published so far
concerning a possible application for the treatment of
osteomyelitis of the long bones [14,19]. Our results
confirm, on a larger population, previous studies,
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age 18 months follow-up, independently on the isolated
pathogen. Of the two patients showing recurrent infec-
tion, one had a polymicrobial ethiology (P. aeruginosa,
S. aureus and Enterococcus spp.), while in the other an
MRSA was isolated at time of surgery. A third patient re-
quired a plastic procedure 8 months after bioglass implant
and was considered a failure, according to success/failure
criteria used in the present study. Further analysis of the
failed cases suggests, for patient 7, an insufficient filling of
the bone defect, since he had a long infected nail crossing
both the tibia and femur, after a knee arthrodesis, that was
removed by us at the time of debridement and bioglass
application. Filling such a large defect was not feasible in
this particular case. In a previous study on 11 patients,
Lindfors and coauthors already hypothesized that out-
come after BAG-S53P4 treatment might be related to
proper filling of the cavities [14], and we think this was
not achieved in this particular case.
An effective filling of large bone defects, consequent
to infection bone matrix dissolution, debridement sur-
gery and often associated to vascular defects, represents
an important issue for bioactive materials since the dead
space may easily harbor bacteria [33].
The other two failed patients shared soft tissue defects,
that might have impaired the final outcome. Both of
them were candidate to a simultaneous flap coverage at
the time of debridement, that had not been undertaken
because direct closure was finally achieved. In spite of
this, both suffered healing wound problem after surgery
and one of them finally received a fascio-cutaneous flap,
with resolution of the septic process, while the other re-
fuses further surgery, in the presence of an intermit-
tently draining fistula.
Conclusions
Following this experience, bioglass application is now
recommended in our practice for those cases in which
we may achieve a satisfactory filling of the defect and an
adequate soft tissue coverage.
Limitations to the present study include the still rela-
tively small limited population of patients and follow-up
that, however, largely exceeded those previously published.
Another limitation of the present study is the lack of a
comparative series of patients, treated with other currently
available surgical options, including surgical debridement
and bone grafting or antibiotic-loaded bone substitutes.
In this regard it should be noted, however, that pro-
spective comparative studies on different surgical treat-
ments of osteomyelitis are extremely rare in the literature
and difficult to perform, due to the high variability of the
cases and to the challenging randomization process. For
this reason in next future, it could be interesting to inves-
tigate the efficacy and safety of bioglass compared to twoother retrospective case series, treated according to a dif-
ferent surgical protocol.
The in vitro and in vivo reported results do reinforce
previous observations on the efficacy of BAG-S53P4 for
the treatment of chronic osteomyelitis of the long bones,
also in the presence of multi-resistant strains and in im-
munocompromised hosts, without relevant side effects
and without the need for locally adding antibiotics.
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